Literature DB >> 31702583

Structural analysis of free and liganded forms of the Fab fragment of a high-affinity anti-cocaine antibody, h2E2.

Kemin Tan1, Min Zhou2, Angela J Ahrendt2, Norma E C Duke2, Nassif Tabaja3, William J Ball4, Terence L Kirley4, Andrew B Norman4, Andrzej Joachimiak1, Marianne Schiffer1, Rosemarie Wilton2, P Raj Pokkuluri1.   

Abstract

A high-affinity anti-cocaine monoclonal antibody, designated h2E2, is entering phase 1 clinical trials for cocaine abuse therapy. To gain insight into the molecular details of its structure that are important for binding cocaine and cocaine metabolites, the Fab fragment was generated and crystallized with and without ligand. Structures of the unliganded Fab and the Fab fragment bound to benzoylecgonine were determined, and were compared with each other and with other crystallized anti-cocaine antibodies. The affinity of the h2E2 antibody for cocaine is 4 nM, while that of the cocaine metabolite benzoylecgonine is 20 nM. Both are higher than the reported affinity for cocaine of the two previously crystallized anti-cocaine antibodies. Consistent with cocaine fluorescent quenching binding studies for the h2E2 mAb, four aromatic residues in the CDR regions of the Fab (TyrL32, TyrL96, TrpL91 and TrpH33) were found to be involved in ligand binding. The aromatic side chains surround and trap the tropane moiety of the ligand in the complex structure, forming significant van der Waals interactions which may account for the higher affinity observed for the h2E2 antibody. A water molecule mediates hydrogen bonding between the antibody and the carbonyl group of the benzoyl ester. The affinity of binding to h2E2 of benzoylecgonine differs only by a factor of five compared with that of cocaine; therefore, it is suggested that h2E2 would bind cocaine in the same way as observed in the Fab-benzoylecgonine complex, with minor rearrangements of some hypervariable segments of the antibody.

Entities:  

Keywords:  Fab fragment; antigen-binding fragment; benzoylecgonine complex; crystal structure; h2E2; high-affinity anti-cocaine antibody

Mesh:

Substances:

Year:  2019        PMID: 31702583      PMCID: PMC6839822          DOI: 10.1107/S2053230X19013608

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  41 in total

1.  Molecular replacement with MOLREP.

Authors:  Alexei Vagin; Alexei Teplyakov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

2.  An antidote for acute cocaine toxicity.

Authors:  Jennifer B Treweek; Kim D Janda
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

3.  Crystal structure of a cocaine-binding antibody.

Authors:  N A Larsen; B Zhou; A Heine; P Wirsching; K D Janda; I A Wilson
Journal:  J Mol Biol       Date:  2001-08-03       Impact factor: 5.469

4.  A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments.

Authors:  A Skerra
Journal:  Gene       Date:  1994-04-08       Impact factor: 3.688

5.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

6.  A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice.

Authors:  Andrew B Norman; Michael R Tabet; Mantana K Norman; William R Buesing; Amadeo J Pesce; William J Ball
Journal:  J Pharmacol Exp Ther       Date:  2006-10-05       Impact factor: 4.030

7.  Vaccine pharmacotherapy for the treatment of cocaine dependence.

Authors:  Bridget A Martell; Ellen Mitchell; James Poling; Kishor Gonsai; Thomas R Kosten
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

8.  Efficacy of a therapeutic cocaine vaccine in rodent models.

Authors:  B S Fox; K M Kantak; M A Edwards; K M Black; B K Bollinger; A J Botka; T L French; T L Thompson; V C Schad; J L Greenstein; M L Gefter; M A Exley; P A Swain; T J Briner
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

9.  Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli.

Authors:  A Skerra
Journal:  Gene       Date:  1994-12-30       Impact factor: 3.688

10.  Salvage of failed protein targets by reductive alkylation.

Authors:  Kemin Tan; Youngchang Kim; Catherine Hatzos-Skintges; Changsoo Chang; Marianne Cuff; Gekleng Chhor; Jerzy Osipiuk; Karolina Michalska; Boguslaw Nocek; Hao An; Gyorgy Babnigg; Lance Bigelow; Grazyna Joachimiak; Hui Li; Jamey Mack; Magdalena Makowska-Grzyska; Natalia Maltseva; Rory Mulligan; Christine Tesar; Min Zhou; Andrzej Joachimiak
Journal:  Methods Mol Biol       Date:  2014
View more
  4 in total

1.  Multi-domain unfolding of the Fab fragment of a humanized anti-cocaine mAb characterized by non-reducing SDS-PAGE.

Authors:  Terence L Kirley; Andrew B Norman
Journal:  Biochem Biophys Res Commun       Date:  2020-09-26       Impact factor: 3.575

2.  Tyrosine nitration of a humanized anti-cocaine mAb differentially affects ligand binding of cocaine and its metabolites.

Authors:  Terence L Kirley; Kenneth D Greis; Andrew B Norman
Journal:  Biochem Biophys Rep       Date:  2022-05-14

3.  Isothermal titration calorimetry determination of thermodynamics of binding of cocaine and its metabolites to humanized h2E2 anti-cocaine mAb.

Authors:  Terence L Kirley; Andrew B Norman
Journal:  Biochem Biophys Rep       Date:  2022-09-24

4.  Cocaine binding to the Fab fragment of a humanized anti-cocaine mAb quantitated by dye absorption and fluorescence spectroscopy.

Authors:  Terence L Kirley; Andrew B Norman
Journal:  J Immunol Methods       Date:  2021-07-21       Impact factor: 2.287

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.